Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company and some important upcoming milestones, including data from Frangile X and Angelman syndrome clinical trials.
Ovid Therapeutics is a New York-based, biopharmaceutical company using its BoldMedicine approach to develop therapies that transform the lives of patients with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies and has initiated a Phase 1b/2a trial of OV935.
For more information on Ovid, visit http://www.ovidrx.com/.